S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study-Reference-Cited by-同舟云学术

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study

Published:2017 Issue:1 Volume:2 Page:e000135
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Baba Hideo,Yamada Yasuhide,Takahari Daisuke,Matsumoto Hiroshi,Yoshida Kazuhiro,Nakamura Masato,Yoshida Motoki,Iwamoto Shigeyoshi,Shimada Ken,Komatsu Yoshito,Sasaki Yasutsuna,Satoh Taroh,Takahashi Keiichi,Mishima Hideyuki,Muro Kei,Watanabe Masahiko,Sakata Yuh,Morita Satoshi,Shimada Yasuhiro,Sugihara Kenichi

Funder

Taiho Pharmaceutical Co. Ltd.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference13 articles.

1. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study;Tournigand;J Clin Oncol,2004

2. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer;Cassidy;J Clin Oncol,2008

3. S-1 for the treatment of gastrointestinal cancer;Satoh;Expert Opin Pharmacother,2012

4. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial;Yamada;Lancet Oncol,2013

5. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study;Saltz;J Clin Oncol,2008

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall survival with non-proportional hazards in first-line treatment for patients with metastatic colorectal cancer: Systematic review and network meta-analysis;Heliyon;2024-08

2. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study);Acta Oncologica;2024-05-02

3. Intestinal Perforation in a patient with peritoneal carcinomatosis from colon cancer treated with Regorafenib. Description of a case and review of the literature;Radiology Case Reports;2024-05

4. Effect of a combination of oxaliplatin and fluoropyrimidine derivative molecule S-1 on expression levels of IL-9 and CysLTR-1 in a rat model of colon cancer;Tropical Journal of Pharmaceutical Research;2022-08-21

5. Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer;European Journal of Cancer;2022-05